Aflibercept
Therapeutic Indications
Aflibercept is indicated for:
Visual impairment due to diabetic macular oedema (DME)
Irrespective of gender only Adults (18 years old or older)
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravitreal - 2 mg once every month
Neovascular (wet) age-related macular degeneration (AMD)
Irrespective of gender only Adults (18 years old or older)
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravitreal - 2 mg once every month
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
Irrespective of gender only Adults (18 years old or older)
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravitreal - 2 mg once every month
Visual impairment due to myopic choroidal neovascularisation (myopic CNV)
Irrespective of gender only Adults (18 years old or older)
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravitreal - 2 mg once every month
Metastatic colorectal cancer (MCRC)
Irrespective of gender only Adults (18 years old or older)
Aflibercept in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 4 mg/kg once every 2 weeks
Contraindications
Active ingredient Aflibercept is contraindicated in the following cases:
Ocular, periocular, intraocular inflammation or infection
No gender/age discrimination
Active or suspected ocular or periocular infection.
Active severe intraocular inflammation.